Loading... (0%)
About liver disease

Targeting
unmet patient
needs

Our R&D efforts are focused on
bringing new medicines to market
for patients with serious diseases
whose treatment options are
limited or non-existent,
as for NASH.

Read more

Our mission:
therapeutic
innovation

Our translational disease driven
approach is the strength of our R&D.
At Genfit, we believe in a full
comprehension of a disease
to discover therapeutic and
diagnostic new solutions.

Read more

Promising
drug
programs

The rationale of our pipeline
is to allow specialists physicians
to change life of their patients
thanks to our medicines.

Read more

Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs...
Learn more

Press releases
  • GENFIT: First quarter 2016 financial information
    04/26/2016
  • GENFIT to begin Elafibranor clinical program in PBC
    03/31/2016
  • GENFIT: Presentations at EASL/ILC 2016 Highlight Progress in NASH Treatment, Biomarker Diagnostics, and Programs Targeting Fibrotic Diseases
    03/30/2016
  • GENFIT announces enrollment of first patient in RESOLVE-IT, the pivotal Phase 3 clinical trial of Elafibranor in NASH
    03/10/2016
Events